Search

Your search keyword '"Morice, Pierre‐Marie"' showing total 33 results
Start Over Author "Morice, Pierre‐Marie"
33 results on '"Morice, Pierre‐Marie"'

2. The OVAREX study: Establishment of ex vivo ovarian cancer models to validate innovative therapies and to identify predictive biomarkers

Author

Thorel, Lucie, Divoux, Jordane, Lequesne, Justine, Babin, Guillaume, Morice, Pierre-Marie, Florent, Romane, Desmartin, Guillaume, Lecouflet, Lucie, Marde Alagama, Chloé, Leconte, Alexandra, Clarisse, Bénédicte, Briand, Mélanie, Rouzier, Roman, Gaichies, Léopold, Martin-Françoise, Sandrine, Le Brun, Jean-François, Denoyelle, Christophe, Vigneron, Nicolas, Jeanne, Corinne, Blanc-Fournier, Cécile, Leman, Raphaël, Vaur, Dominique, Figeac, Martin, Meryet-Figuiere, Matthieu, Joly, Florence, Weiswald, Louis-Bastien, Poulain, Laurent, and Dolivet, Enora

Published
2024
Full Text
View/download PDF

5. Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma

Author

Thorel, Lucie, Morice, Pierre-Marie, Paysant, Hippolyte, Florent, Romane, Babin, Guillaume, Thomine, Cécilia, Perréard, Marion, Abeilard, Edwige, Giffard, Florence, Brotin, Emilie, Denoyelle, Christophe, Villenet, Céline, Sebda, Shéhérazade, Briand, Mélanie, Joly, Florence, Dolivet, Enora, Goux, Didier, Blanc-Fournier, Cécile, Jeanne, Corinne, Villedieu, Marie, Meryet-Figuiere, Matthieu, Figeac, Martin, Poulain, Laurent, and Weiswald, Louis-Bastien

Published
2023
Full Text
View/download PDF

9. Arterial hypertension associated with PARPi: A meta‐analysis of 41 placebo randomized controlled trials combined with a World Health Organization's pharmacovigilance study.

Author

Blaize, Clémence, Surtouque, Ellina, Font, Jonaz, Dolladille, Charles, Postel‐Vinay, Sophie, Da Silva, Angélique, Alexandre, Joachim, and Morice, Pierre‐Marie

Subjects
POLY ADP ribose, UBIQUINONES, HYPERTENSION, WORLD health, SURVIVAL analysis (Biometry), RANDOMIZED controlled trials, PLACEBOS
Abstract

Background: Arterial hypertension has been recently reported from randomized controlled trials (RCTs) assessing poly (ADP‐ribose) polymerase inhibitor (PARPi). Objective: In a context of increasing use of PARPi, it is crucial to properly assess risk and incidence of this adverse event for clinical practice. Methods: We performed a systematic review and meta‐analysis in MEDLINE, Cochrane CENTRAL and ClinicalTrials.gov up to January 4, 2023 with an ongoing surveillance up to June 7, 2023. RCTs comparing PARPi to placebo in adult patients with solid tumors were included if hypertension was reported. The primary outcome was the summary risk ratio (RR, with 95% CIs) of any hypertension of PARPi class in placebo RCTs. Secondary outcomes were the summary risk and incidence of hypertension of each individual PARPi. To provide clinical features of PARPi‐associated hypertension, we independently queried the WHO's pharmacovigilance database, up to September 1, 2022. Results: In total, 41 placebo RCTs (n = 15 264 adult patients) were included. PARPi class was not associated with an increased risk of hypertension compared with placebo. In individual analyses, the risk of hypertension was lower with olaparib than placebo (RR 0.77 [95% CI: 0.68–0.86], P < 0.01; I2 = 19%, χ2P = 0.26). Niraparib monotherapy increased the risk of any (RR 2.84 [95% CI: 1.76–4.57], P < 0.01; I2 = 66%, χ2P = 0.01) hypertension with a summary incidence of 19.87% (95% CI: 15.23–25.50). In real‐life setting, niraparib‐associated hypertension occurs within 20 days and was serious in 66%. Co‐prescription of at least one antihypertensive or therapy‐induced hypertension was reported in 20.5% or 14.4% of cases, respectively. Conclusions: In a context of extensive assessment of niraparib in combination, these data reinforce the need of a close monitoring of this adverse event to preserve its clinical benefit on patients' survival. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. NSAIDs for Pain Control During the Peri-Operative Period of Hip Fracture Surgery: A Systematic Review

Author

Pommier, Wilhelm, primary, Minoc, Elise-Marie, additional, Morice, Pierre-Marie, additional, Lescure, Pascale, additional, Guillaume, Cyril, additional, Lafont, Claire, additional, Fischer, Marc-Olivier, additional, Boddaert, Jacques, additional, Thietart, Sara, additional, Lelong-Boulouard, Véronique, additional, Beauplet, Bérengère, additional, and Villain, Cédric, additional

Published
2023
Full Text
View/download PDF

11. Data from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience

Author

Marmouset, Vincent, primary, Decroocq, Justine, primary, Garciaz, Sylvain, primary, Etienne, Gabriel, primary, Belhabri, Amine, primary, Bertoli, Sarah, primary, Gastaud, Lauris, primary, Simand, Célestine, primary, Chantepie, Sylvain, primary, Uzunov, Madalina, primary, Genthon, Alexis, primary, Berthon, Céline, primary, Chiche, Edmond, primary, Dumas, Pierre-Yves, primary, Vargaftig, Jacques, primary, Salmeron, Géraldine, primary, Lemasle, Emilie, primary, Tavernier, Emmanuelle, primary, Delage, Jérémy, primary, Loirat, Marion, primary, Morineau, Nadine, primary, Blanc-Durand, Félix, primary, Pautier, Patricia, primary, Vergé, Véronique, primary, Auger, Nathalie, primary, Thomas, Myrtille, primary, Stefani, Laetitia, primary, Lepelley, Marion, primary, Boyer, Thomas, primary, Thepot, Sylvain, primary, Gourin, Marie-Pierre, primary, Bourquard, Pascal, primary, Duchmann, Matthieu, primary, Morice, Pierre-Marie, primary, Michallet, Mauricette, primary, Adès, Lionel, primary, Fenaux, Pierre, primary, Récher, Christian, primary, Dombret, Hervé, primary, Pagès, Arnaud, primary, Marzac, Christophe, primary, Leary, Alexandra, primary, and Micol, Jean-Baptiste, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figure 4 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience

Author

Marmouset, Vincent, primary, Decroocq, Justine, primary, Garciaz, Sylvain, primary, Etienne, Gabriel, primary, Belhabri, Amine, primary, Bertoli, Sarah, primary, Gastaud, Lauris, primary, Simand, Célestine, primary, Chantepie, Sylvain, primary, Uzunov, Madalina, primary, Genthon, Alexis, primary, Berthon, Céline, primary, Chiche, Edmond, primary, Dumas, Pierre-Yves, primary, Vargaftig, Jacques, primary, Salmeron, Géraldine, primary, Lemasle, Emilie, primary, Tavernier, Emmanuelle, primary, Delage, Jérémy, primary, Loirat, Marion, primary, Morineau, Nadine, primary, Blanc-Durand, Félix, primary, Pautier, Patricia, primary, Vergé, Véronique, primary, Auger, Nathalie, primary, Thomas, Myrtille, primary, Stefani, Laetitia, primary, Lepelley, Marion, primary, Boyer, Thomas, primary, Thepot, Sylvain, primary, Gourin, Marie-Pierre, primary, Bourquard, Pascal, primary, Duchmann, Matthieu, primary, Morice, Pierre-Marie, primary, Michallet, Mauricette, primary, Adès, Lionel, primary, Fenaux, Pierre, primary, Récher, Christian, primary, Dombret, Hervé, primary, Pagès, Arnaud, primary, Marzac, Christophe, primary, Leary, Alexandra, primary, and Micol, Jean-Baptiste, primary

Published
2023
Full Text
View/download PDF

13. Supplementary Table 3 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience

Author

Marmouset, Vincent, primary, Decroocq, Justine, primary, Garciaz, Sylvain, primary, Etienne, Gabriel, primary, Belhabri, Amine, primary, Bertoli, Sarah, primary, Gastaud, Lauris, primary, Simand, Célestine, primary, Chantepie, Sylvain, primary, Uzunov, Madalina, primary, Genthon, Alexis, primary, Berthon, Céline, primary, Chiche, Edmond, primary, Dumas, Pierre-Yves, primary, Vargaftig, Jacques, primary, Salmeron, Géraldine, primary, Lemasle, Emilie, primary, Tavernier, Emmanuelle, primary, Delage, Jérémy, primary, Loirat, Marion, primary, Morineau, Nadine, primary, Blanc-Durand, Félix, primary, Pautier, Patricia, primary, Vergé, Véronique, primary, Auger, Nathalie, primary, Thomas, Myrtille, primary, Stefani, Laetitia, primary, Lepelley, Marion, primary, Boyer, Thomas, primary, Thepot, Sylvain, primary, Gourin, Marie-Pierre, primary, Bourquard, Pascal, primary, Duchmann, Matthieu, primary, Morice, Pierre-Marie, primary, Michallet, Mauricette, primary, Adès, Lionel, primary, Fenaux, Pierre, primary, Récher, Christian, primary, Dombret, Hervé, primary, Pagès, Arnaud, primary, Marzac, Christophe, primary, Leary, Alexandra, primary, and Micol, Jean-Baptiste, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Table 1 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience

Author

Marmouset, Vincent, primary, Decroocq, Justine, primary, Garciaz, Sylvain, primary, Etienne, Gabriel, primary, Belhabri, Amine, primary, Bertoli, Sarah, primary, Gastaud, Lauris, primary, Simand, Célestine, primary, Chantepie, Sylvain, primary, Uzunov, Madalina, primary, Genthon, Alexis, primary, Berthon, Céline, primary, Chiche, Edmond, primary, Dumas, Pierre-Yves, primary, Vargaftig, Jacques, primary, Salmeron, Géraldine, primary, Lemasle, Emilie, primary, Tavernier, Emmanuelle, primary, Delage, Jérémy, primary, Loirat, Marion, primary, Morineau, Nadine, primary, Blanc-Durand, Félix, primary, Pautier, Patricia, primary, Vergé, Véronique, primary, Auger, Nathalie, primary, Thomas, Myrtille, primary, Stefani, Laetitia, primary, Lepelley, Marion, primary, Boyer, Thomas, primary, Thepot, Sylvain, primary, Gourin, Marie-Pierre, primary, Bourquard, Pascal, primary, Duchmann, Matthieu, primary, Morice, Pierre-Marie, primary, Michallet, Mauricette, primary, Adès, Lionel, primary, Fenaux, Pierre, primary, Récher, Christian, primary, Dombret, Hervé, primary, Pagès, Arnaud, primary, Marzac, Christophe, primary, Leary, Alexandra, primary, and Micol, Jean-Baptiste, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Figure 2 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience

Author

Marmouset, Vincent, primary, Decroocq, Justine, primary, Garciaz, Sylvain, primary, Etienne, Gabriel, primary, Belhabri, Amine, primary, Bertoli, Sarah, primary, Gastaud, Lauris, primary, Simand, Célestine, primary, Chantepie, Sylvain, primary, Uzunov, Madalina, primary, Genthon, Alexis, primary, Berthon, Céline, primary, Chiche, Edmond, primary, Dumas, Pierre-Yves, primary, Vargaftig, Jacques, primary, Salmeron, Géraldine, primary, Lemasle, Emilie, primary, Tavernier, Emmanuelle, primary, Delage, Jérémy, primary, Loirat, Marion, primary, Morineau, Nadine, primary, Blanc-Durand, Félix, primary, Pautier, Patricia, primary, Vergé, Véronique, primary, Auger, Nathalie, primary, Thomas, Myrtille, primary, Stefani, Laetitia, primary, Lepelley, Marion, primary, Boyer, Thomas, primary, Thepot, Sylvain, primary, Gourin, Marie-Pierre, primary, Bourquard, Pascal, primary, Duchmann, Matthieu, primary, Morice, Pierre-Marie, primary, Michallet, Mauricette, primary, Adès, Lionel, primary, Fenaux, Pierre, primary, Récher, Christian, primary, Dombret, Hervé, primary, Pagès, Arnaud, primary, Marzac, Christophe, primary, Leary, Alexandra, primary, and Micol, Jean-Baptiste, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Table 4 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience

Author

Marmouset, Vincent, primary, Decroocq, Justine, primary, Garciaz, Sylvain, primary, Etienne, Gabriel, primary, Belhabri, Amine, primary, Bertoli, Sarah, primary, Gastaud, Lauris, primary, Simand, Célestine, primary, Chantepie, Sylvain, primary, Uzunov, Madalina, primary, Genthon, Alexis, primary, Berthon, Céline, primary, Chiche, Edmond, primary, Dumas, Pierre-Yves, primary, Vargaftig, Jacques, primary, Salmeron, Géraldine, primary, Lemasle, Emilie, primary, Tavernier, Emmanuelle, primary, Delage, Jérémy, primary, Loirat, Marion, primary, Morineau, Nadine, primary, Blanc-Durand, Félix, primary, Pautier, Patricia, primary, Vergé, Véronique, primary, Auger, Nathalie, primary, Thomas, Myrtille, primary, Stefani, Laetitia, primary, Lepelley, Marion, primary, Boyer, Thomas, primary, Thepot, Sylvain, primary, Gourin, Marie-Pierre, primary, Bourquard, Pascal, primary, Duchmann, Matthieu, primary, Morice, Pierre-Marie, primary, Michallet, Mauricette, primary, Adès, Lionel, primary, Fenaux, Pierre, primary, Récher, Christian, primary, Dombret, Hervé, primary, Pagès, Arnaud, primary, Marzac, Christophe, primary, Leary, Alexandra, primary, and Micol, Jean-Baptiste, primary

Published
2023
Full Text
View/download PDF

17. Supplementary Figure 3 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience

Author

Marmouset, Vincent, primary, Decroocq, Justine, primary, Garciaz, Sylvain, primary, Etienne, Gabriel, primary, Belhabri, Amine, primary, Bertoli, Sarah, primary, Gastaud, Lauris, primary, Simand, Célestine, primary, Chantepie, Sylvain, primary, Uzunov, Madalina, primary, Genthon, Alexis, primary, Berthon, Céline, primary, Chiche, Edmond, primary, Dumas, Pierre-Yves, primary, Vargaftig, Jacques, primary, Salmeron, Géraldine, primary, Lemasle, Emilie, primary, Tavernier, Emmanuelle, primary, Delage, Jérémy, primary, Loirat, Marion, primary, Morineau, Nadine, primary, Blanc-Durand, Félix, primary, Pautier, Patricia, primary, Vergé, Véronique, primary, Auger, Nathalie, primary, Thomas, Myrtille, primary, Stefani, Laetitia, primary, Lepelley, Marion, primary, Boyer, Thomas, primary, Thepot, Sylvain, primary, Gourin, Marie-Pierre, primary, Bourquard, Pascal, primary, Duchmann, Matthieu, primary, Morice, Pierre-Marie, primary, Michallet, Mauricette, primary, Adès, Lionel, primary, Fenaux, Pierre, primary, Récher, Christian, primary, Dombret, Hervé, primary, Pagès, Arnaud, primary, Marzac, Christophe, primary, Leary, Alexandra, primary, and Micol, Jean-Baptiste, primary

Published
2023
Full Text
View/download PDF

18. Supplementary Table 2 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience

Author

Marmouset, Vincent, primary, Decroocq, Justine, primary, Garciaz, Sylvain, primary, Etienne, Gabriel, primary, Belhabri, Amine, primary, Bertoli, Sarah, primary, Gastaud, Lauris, primary, Simand, Célestine, primary, Chantepie, Sylvain, primary, Uzunov, Madalina, primary, Genthon, Alexis, primary, Berthon, Céline, primary, Chiche, Edmond, primary, Dumas, Pierre-Yves, primary, Vargaftig, Jacques, primary, Salmeron, Géraldine, primary, Lemasle, Emilie, primary, Tavernier, Emmanuelle, primary, Delage, Jérémy, primary, Loirat, Marion, primary, Morineau, Nadine, primary, Blanc-Durand, Félix, primary, Pautier, Patricia, primary, Vergé, Véronique, primary, Auger, Nathalie, primary, Thomas, Myrtille, primary, Stefani, Laetitia, primary, Lepelley, Marion, primary, Boyer, Thomas, primary, Thepot, Sylvain, primary, Gourin, Marie-Pierre, primary, Bourquard, Pascal, primary, Duchmann, Matthieu, primary, Morice, Pierre-Marie, primary, Michallet, Mauricette, primary, Adès, Lionel, primary, Fenaux, Pierre, primary, Récher, Christian, primary, Dombret, Hervé, primary, Pagès, Arnaud, primary, Marzac, Christophe, primary, Leary, Alexandra, primary, and Micol, Jean-Baptiste, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Figure 1 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience

Author

Marmouset, Vincent, primary, Decroocq, Justine, primary, Garciaz, Sylvain, primary, Etienne, Gabriel, primary, Belhabri, Amine, primary, Bertoli, Sarah, primary, Gastaud, Lauris, primary, Simand, Célestine, primary, Chantepie, Sylvain, primary, Uzunov, Madalina, primary, Genthon, Alexis, primary, Berthon, Céline, primary, Chiche, Edmond, primary, Dumas, Pierre-Yves, primary, Vargaftig, Jacques, primary, Salmeron, Géraldine, primary, Lemasle, Emilie, primary, Tavernier, Emmanuelle, primary, Delage, Jérémy, primary, Loirat, Marion, primary, Morineau, Nadine, primary, Blanc-Durand, Félix, primary, Pautier, Patricia, primary, Vergé, Véronique, primary, Auger, Nathalie, primary, Thomas, Myrtille, primary, Stefani, Laetitia, primary, Lepelley, Marion, primary, Boyer, Thomas, primary, Thepot, Sylvain, primary, Gourin, Marie-Pierre, primary, Bourquard, Pascal, primary, Duchmann, Matthieu, primary, Morice, Pierre-Marie, primary, Michallet, Mauricette, primary, Adès, Lionel, primary, Fenaux, Pierre, primary, Récher, Christian, primary, Dombret, Hervé, primary, Pagès, Arnaud, primary, Marzac, Christophe, primary, Leary, Alexandra, primary, and Micol, Jean-Baptiste, primary

Published
2023
Full Text
View/download PDF

22. Transverse Myelitis Following SARS‐CoV‐2 Vaccination: A Pharmacoepidemiological Study in the World Health Organization's Database

Author

Nguyen, Sophie, primary, Bastien, Etienne, additional, Chretien, Basile, additional, Sassier, Marion, additional, Defer, Gilles, additional, Nehme, Ahmad, additional, Lelong‐Boulouard, Véronique, additional, Alexandre, Joachim, additional, Fedrizzi, Sophie, additional, and Morice, Pierre‐Marie, additional

Published
2022
Full Text
View/download PDF

23. Association between road traffic accidents and drugs belonging to the antiseizure medications class: A pharmacovigilance analysis in VigiBase

Author

Chrétien, Basile, primary, Nguyen, Sophie, additional, Dolladille, Charles, additional, Morice, Pierre‐Marie, additional, Heraudeau, Marie, additional, Loilier, Magalie, additional, Fedrizzi, Sophie, additional, Bourgine, Joanna, additional, Cesbron, Alexandre, additional, Alexandre, Joachim, additional, Bocca, Marie‐Laure, additional, Freret, Thomas, additional, and Lelong‐Boulouard, Véronique, additional

Published
2022
Full Text
View/download PDF

26. Association between road traffic accidents and drugs belonging to the antiseizure medications class: A pharmacovigilance analysis in VigiBase.

Author

Chrétien, Basile, Nguyen, Sophie, Dolladille, Charles, Morice, Pierre‐Marie, Heraudeau, Marie, Loilier, Magalie, Fedrizzi, Sophie, Bourgine, Joanna, Cesbron, Alexandre, Alexandre, Joachim, Bocca, Marie‐Laure, Freret, Thomas, and Lelong‐Boulouard, Véronique

Subjects
DRUG traffic, DRUG interactions, TRAFFIC accidents, DRUG monitoring, DRUGS, DISEASE risk factors, NALTREXONE
Abstract

Aims: Due to their central mechanism of action, antiseizure medications (ASMs) could lead to adverse effects likely to impair driving skills. Their extended use to neuropsychiatric disorders makes it a class of drugs to monitor for their road traffic accidental (RTA) potential. We aimed to assess the reporting association between ASMs and RTAs using the World Health Organization pharmacovigilance database (VigiBase). Methods: We performed a disproportionality analysis to compute adjusted reporting odds ratios to evaluate the strength of reporting association between ASMs and RTAs. A univariate analysis using the reporting odds‐ratio was used to assess drug–drug interactions between ASMs and RTAs. Results: There were 1 341 509 reports associated with at least 1 ASM in VigiBase of whom 2.91‰ were RTAs reports. Eight ASMs were associated with higher reporting of RTAs compared to others (ranging from 1.35 [95% confidence interval 1.11–1.64] for lamotrigine to 4.36 [95% confidence interval 3.56–5.32] for cannabis). Eight significant drug–drug interactions were found between ASMs and the onset of RTA, mainly involving CYP450 induction. Conclusion: A significant safety signal between RTAs and some ASMs was identified. Association of several ASMs might further increase the occurrence of RTA. ASMs prescription in patients with identified risk factors of RTA should be considered with caution. Study number: ClinicalTrials.gov, NCT04480996. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

27. Poly(ADP‐ribose)polymerase inhibitors‐associated myeloid neoplasms: a retrospective study from the French Network of Pharmacovigilance centres

Author

Morice, Pierre‐Marie, primary, Genthon, Alexis, additional, Boyer, Thomas, additional, Bihan, Kevin, additional, Mahé, Julien, additional, Sourisseau, Anthony, additional, Peyrouzet, Hélène, additional, Miremont, Ghada, additional, Lepelley, Marion, additional, Stefani, Laetitia, additional, Gaboriau, Louise, additional, Rocher, Fanny, additional, Aquaronne, Danièle, additional, Le Beller, Christine, additional, Allouchery, Marion, additional, Azzouz, Brahim, additional, Massy, Nathalie, additional, Alt‐Tebacher, Martine, additional, Simand, Célestine, additional, Herbrecht, Raoul, additional, Chrétien, Basile, additional, Dolladille, Charles, additional, Chantepie, Sylvain, additional, and Alexandre, Joachim, additional

Published
2021
Full Text
View/download PDF

28. Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis

Author

Dolladille, Charles, primary, Akroun, Julia, additional, Morice, Pierre-Marie, additional, Dompmartin, Anne, additional, Ezine, Emilien, additional, Sassier, Marion, additional, Da-Silva, Angélique, additional, Plane, Anne-Flore, additional, Legallois, Damien, additional, L’Orphelin, Jean-Mathieu, additional, and Alexandre, Joachim, additional

Published
2021
Full Text
View/download PDF

29. The lncRNA ‘UCA1’ modulates the response to chemotherapy of ovarian cancer through direct binding to miR‐27a‐5p and control of UBE2N levels

Author

Wambecke, Anaïs, primary, Ahmad, Mohammad, additional, Morice, Pierre‐Marie, additional, Lambert, Bernard, additional, Weiswald, Louis‐Bastien, additional, Vernon, Mégane, additional, Vigneron, Nicolas, additional, Abeilard, Edwige, additional, Brotin, Emilie, additional, Figeac, Martin, additional, Gauduchon, Pascal, additional, Poulain, Laurent, additional, Denoyelle, Christophe, additional, and Meryet‐Figuiere, Matthieu, additional

Published
2021
Full Text
View/download PDF

30. Poly(ADP‐ribose)polymerase inhibitors‐associated myeloid neoplasms: a retrospective study from the French Network of Pharmacovigilance centres.

Author

Morice, Pierre‐Marie, Genthon, Alexis, Boyer, Thomas, Bihan, Kevin, Mahé, Julien, Sourisseau, Anthony, Peyrouzet, Hélène, Miremont, Ghada, Lepelley, Marion, Stefani, Laetitia, Gaboriau, Louise, Rocher, Fanny, Aquaronne, Danièle, Le Beller, Christine, Allouchery, Marion, Azzouz, Brahim, Massy, Nathalie, Alt‐Tebacher, Martine, Simand, Célestine, and Herbrecht, Raoul

Subjects
*OVARIAN cancer, *ACUTE myeloid leukemia, *TUMORS
Abstract

The distribution of genetic mutations affects seven out of 20 patients (35%), mainly related to I TP53 i (six patients, 30%), I TET2 i (two patients, 10%) and I DNMT3A i (two patients, 10%). During the long-term follow-ups of randomized controlled trials (RCTs), some cases of therapy-associated myeloid neoplasms (t-MNs), including myelodysplastic syndrome (t-MDS) and acute myeloid leukaemia (t-AML), were reported both in the poly(ADP-ribose)polymerase inhibitors (PARPi) and control arms. For the 21 patients, t-MNs occurred after a median latency period of 18-2 (IQR 10-0-30-0) months following first PARPi exposure. Among them, 113 out of 32 662 patients (0-3%) with OC experienced t-MNs after a mean time from first primary cancer diagnosis of 5-3 years for t-MDS ( I n i = 47 patients) and 4-5 years for t-AML ( I n i = 66 patients), with an overall standardized incidence ratio of 5-8 (4-8-6-9).8 Our shorter latency may be linked to an underlying clonal haematopoiesis as I TET2 i and I DNMT3A i mutations were frequently found. [Extracted from the article]

Published
2022
Full Text
View/download PDF

31. Automated scoring to assess RAD51-mediated homologous recombination in ovarian patient-derived tumor organoids.

Author

Thorel L, Elie N, Morice PM, Weiswald LB, Florent R, Perréard M, Giffard F, Ricou A, Leman R, Babin G, Lebrun JF, Martin S, Briand M, Lambert B, Joly F, Blanc-Fournier C, Vaur D, Dolivet E, Plancoulaine B, and Poulain L

Abstract

PARP inhibitors (PARPi) have been shown to improve progression-free survival, particularly in homologous recombination deficient (HRD) ovarian cancers. Identifying patients eligible to PARPi is currently based on next-generation sequencing (NGS), but the persistence of genomic scars in tumors after restoration of HR or epigenetic changes can be a limitation. Functional assays could thus be used to improve this profiling and faithfully identify HRD tumors. The RECAP test assesses the formation of RAD51 foci in proliferating cells after irradiation and can be used on tumors as well as on patient-derived tumor organoids (PDTO). However, RAD51 foci scoring is often performed manually without standardization. The purpose of this translational study was to develop an automated tool for scoring RAD51-mediated HR based on whole slide imaging of ovarian PDTO. To that end, we quantified Cyclin A2 and RAD51 immunofluorescence on 9 PDTO models derived from 8 ovarian cancer patients and next compared RECAP test results to genome instability score (GIScar) and to the patient clinical response. We therefore developed a standardized and automatized quantitative histo-imaging tool allowing a comparative RAD51 foci evaluation and thus to define the HR status in PDTO. Our RECAP-based classification was correlated to the GIScar score, offering a new opportunity for standardization of HR assessment in PDTO. This new automated tool to score HR status, that remains to be validated on a large cohort of patients, may thus be used as a complement to NGS-based tests in order to improve the identification of the number of patients eligible to PARPi., (Copyright © 2025. Published by Elsevier Inc.)

Published
2025
Full Text
View/download PDF

33. Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience.

Author

Marmouset V, Decroocq J, Garciaz S, Etienne G, Belhabri A, Bertoli S, Gastaud L, Simand C, Chantepie S, Uzunov M, Genthon A, Berthon C, Chiche E, Dumas PY, Vargaftig J, Salmeron G, Lemasle E, Tavernier E, Delage J, Loirat M, Morineau N, Blanc-Durand F, Pautier P, Vergé V, Auger N, Thomas M, Stefani L, Lepelley M, Boyer T, Thepot S, Gourin MP, Bourquard P, Duchmann M, Morice PM, Michallet M, Adès L, Fenaux P, Récher C, Dombret H, Pagès A, Marzac C, Leary A, and Micol JB

Subjects
Female, Humans, Poly(ADP-ribose) Polymerase Inhibitors adverse effects, Carcinoma, Ovarian Epithelial, Mutation, Germ-Line Mutation, Ovarian Neoplasms drug therapy, Ovarian Neoplasms genetics, Neoplasms, Second Primary diagnosis, Neoplasms, Second Primary epidemiology
Abstract

Purpose: To provide insights into the diagnosis and management of therapy-related myeloid neoplasms (t-MN) following PARP inhibitors (PARPi)., Experimental Design: In a French cancer center, we identified and described the profiles of 13 t-MN diagnosed among 37 patients with ovarian cancer referred to hematology consultation for cytopenia under PARPi. Next, we described these 13 t-MN post-PARPi among 37 t-MN post ovarian cancer according to PARPi exposure. Finally, we described 69 t-MN post-PARPi in a national cohort., Results: From 2016 to 2021, cumulative incidence of t-MN was 3.5% (13/373) among patients with ovarian cancer treated with PARPi. At time of hematologic consultation, patients with t-MN had a longer PARPi exposure (9 vs. 3 months, P = 0.01), lower platelet count (74 vs. 173 G/L, P = 0.0005), and more cytopenias (2 vs. 1, P = 0.0005). Compared with t-MN not exposed to PARPi, patients with t-MN-PARPi had more BRCA1/2 germline mutation (61.5% vs. 0%, P = 0.03) but similar overall survival (OS). In the national cohort, most t-MN post-PARPi had a complex karyotype (61%) associated with a high rate of TP53 mutation (71%). Median OS was 9.6 months (interquartile range, 4-14.6). In multivariate analysis, a longer time between end of PARPi and t-MN (HR, 1.046; P = 0.02), olaparib compared with other PARPi (HR, 5.82; P = 0.003) and acute myeloid leukemia (HR, 2.485; P = 0.01) were associated with shorter OS., Conclusions: In a large series, we described a high incidence of t-MN post-PARPi associated with unfavorable cytogenetic and molecular abnormalities leading to poor OS. Early detection is crucial, particularly in cases of delayed cytopenia., (©2022 American Association for Cancer Research.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results